AU2015301368B2 - Immunogenic composition against Campylobacter jejuni - Google Patents

Abstract

The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing and anti-C. jejuni immune response.

Description

BACKGROUND OF INVENTION

Field of the Invention [0001] The inventive subject matter relates to an immunogenic composition capable of conferring protection against diarrhea caused by Campylobacter jejuni and a method of inducing an immune response against C, jejuni using the immunogenic composition.

Description of Related Art [0002] Campylobacter jejuni is estimated to cause 2.5 million cases annually in the United States and >400 million cases worldwide. In developing countries C. jejuni is, like ETEC, primarily a pediatric disease. The symptoms of Campylobacter enteritis include diarrhea, abdominal pain, fever and sometimes vomiting. Stools usually contain

WO 2016/022412

PCT/US2015/043070 mucus, fecal leukocytes and blood, although watery diarrhea is also observed. The disease is zoonotic, and wild and domesticated birds represent a major reservoir. C. jejuni is a major foodbome infection, most often being associated with contaminated poultry, but major outbreaks have been associated with water or raw milk contamination (44). C. jejuni is also associated with Reiter’s syndrome and inflammatory bowel syndrome, but the major complication of C. jejuni enteritis is Guillain-Barre Syndrome (GBS), a post-infectious polyneuropathy that can result in paralysis (Alios, B.M., J. Infect. Dis 176 (Suppl 2):8125-128 (1997)). The association is due to molecular mimicry between the sialic acid containing-outer core of the lipooligosaceharide (LOS) and human gangliosides (Moran, et al., J. Endotox. Res, 3: 521 (1996)). Thus, antibodies generated against LOS cores result in an autoimmune response to human neural tissue.

[0003] C. jejuni capsular moieties are important in serodetermination. However, despite over 47 Penner serotypes of C. jejuni having been identified, most Campylobacter diarrheal disease is caused by C. jejuni expressing only a limited number of serotypes. Therefore, only selected strains of C. jejuni, predicated on epidemiological studies, provides suitable candidate strains for development of vaccine compositions. However, despite the importance of this organism to human di sease, there are no licensed vaccines against C. jejuni.

[0002] LOS synthesis in Campylobacter is controlled by a number of genes, including genes encoding enzymes involved in biosynthesis of sialic acid for incorporation into LOS. Thus, C. jejuni is one of a limited number of bacteria that can endogenously synthesize sialic acid, a 9 carbon sugar that is found in many mammalian cells. This is

WO 2016/022412

PCT/US2015/043070 consistent with the observed molecular mimicry of LOS and human ganghosides important in GBS (Aspinall, et at, Eur. J. Biochem,, 213: 1029 (1993); Aspinall, et al., Infect. Immun. 62: 2122-2125 (1994); Aspinall, et al,, Bioehem., 33: 241 (1994); SalSoway et al,, Infect. Immun., 64: 2945 (1996)).

[00031 An interesting recent revelation regarding the Campylobacter genome sequence was the presence of a complete set of capsule transport genes similar· to those seen in type ΙΙ/ΙΠ capsule loci in the Enlerobactericeae (Parkhill et al., Nature, 403: 665 (2000); Karlyshev et ai., Mol. Microbiol., 35: 529 (2000)). Subsequent genetic studies in which site-specific mutations were made in several capsule transport genes indicated that the capsule was the serodeterminant of the Penner serotyping scheme (Karlyshev et al., Mol. Microbiol., 35: 529 (2000)). The Penner scheme (or HS for heat stable) is one of two major serotyping schemes of Campylobacters and was originally thought to be based on lipopolysaccharide O side chains (Moran and Penner, J. Appl. Microbiol., 86: 361 (1999)). Currently it is believed that the structures previously described as O side chains are, in fact, capsules.

SUMMARY OF THE INVENTION [0004] The inventive composition relates to an immunogenic composition comprising polysaccharide antigens comprising isolated capsule polysaccharides from a Campylobacter jejuni strain, linked to form polysaccharide polymers, The polysaccharides are isolated from lipooligosaecharide structures and other structures associated with Guillain Barre Syndrome or autoimmune disorders. The embodied composition comprises one or more polysaccharide antigens each comprising isolated ·*»

Λ

2015301368 07 Mar 2018 polysaccharides from the C. jejuni strains selected from the group consisting of HS1, HS1 HS44, HS44, HS2, HS3, HS4₅ HS5, HS13, HS4/13/64, and HS50.

[0004a] In an embodiment there is provided an immunogenic composition against Campylobacter jejuni, comprising one or more polysaccharide antigens, wherein each of said polysaccharide antigens comprises an isolated Campylobacter jejuni capsule polysaccharide derived from a Campylobacter jejuni strain linked to form a repeating polysaccharide polymer comprising 2 or more of said capsule polysaccharides, wherein said Campylobacter jejuni strains are selected from the group consisting of: HS4, HS5, HS4/13/64, and HS50, wherein said immunogenic composition does not contain Campylobacter jejuni lipooligosaccharide structures associated with Guillain Barre Syndrome, wherein the structure ofHS4 is —>3)-L-p-D-ido-Hep-(l—>4)-P-D-GlcNAc-(l—>, with non-stoichiometric MeOPN at C-4 of LD-ido-Hep, wherein the structure of HS4/13/64 is [-»3)-6d-P-D-idoHep-(1—>4)-P-D-GlcNAc-(l—»]_n, with non-stoichiometric MeOPN at C-2 and/or C-7 of 6dido-Hep, and wherein the number of repeats of a capsule polysaccharide “n” is 1 to 100.

[0005] Another embodiment is a method of inducing an immune response by administering an immunogenic composition comprising one or more polysaccharide antigens with each antigen comprising an isolated polysaccharides or polysaccharide polymer derived from a C. jejuni strain where the C. jejuni strains are selected from the group consisting of: HS1, HS1/HS44, HS44, HS, HS3, HS4, HS5, HS13, HS4/13/64, and HS50. The composition is devoid of iipooiigosaccharide structures and other structures associated with Guillain Barre Syndrome or other autoimmune disorders.

[0005a] In an embodiment there is provided a method of inducing an anti-Campylobacter jejuni immune response in a mammal against a Campylobacter jejuni strain selected from the group consisting of HS4, HS5, HS4/13/64, and HS50, comprising:

a. administering the immunogenic composition of the invention to said mammal at a dose range of 0.1 pg to 10 mg per dose; and

b. administering a boosting dose of said immunogenic composition of the invention to said mammal at a dose range of 0.1 pg to 10 mg per dose.

(14389950_l):GGG

4a

2015301368 07 Mar 2018 [0006] Another embodiment is a method of immunizing against C. jejuni strains HS4, HS13,

HS4/HS4/13/64 and HS50 by administering one or more antigens, wherein each antigen comprises an isolated polysaccharide or polysaccharide polymers derived from a C, jejuni strain selected from the group consisting of HS4, HS13, HS4/13/64 and HS50.

[0006a] In an embodiment there is provided a method of inducing an an\\-Campylobacter jejuni immune response in a mammal against a Campylobacter jejuni strain selected from the group consisting of HS4, HS4/13/64, HS5, and HS50, comprising administering 3 doses of the immunogenic composition of the invention to said mammal, at a dose range of 0.1 pg to 10 mg per dose, with or without an adjuvant [0007] Another embodiment is a method of immunizing against C. jejuni strains HS1, HS1/HS44, HS44 by administering one or more antigens, wherein each antigen comprises an isolated polysaccharide or polysaccharide polymer derived from a C jejuni strain selected from the group consisting of C. jejuni strains HS4, HS13, HS4/13/64.

[0007a] In an embodiment there is provided use of an immunogenic composition of the invention in the manufacture of a medicament for inducing an Άγή-Campylobacter jejuni immune response in a mammal against a Campylobacter jejuni strain selected from the group consisting of HS4, HS4/13/64, HS5, and HS50, wherein in said inducing an immune response two doses or three doses of said composition are administered to said mammal, at a dose range of 0.1 pg to 10 mg per dose, with or without an adjuvant.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Alignment of variable CPS loci from C. jejuni HS1 and HS44 Penner type strains. Genes are as indicated in the figure and include: methyl phosphoramidate (MeOPN) biosynthesis and transferase; CPS transport and assembly; putative methyl (14389950_l):GGG

WO 2016/022412

PCT/US2015/043070 transferase; Heptose/deoxyheptose biosynthesis; putative glycosy! transferase; sugar biosynthesis; and hypothetical.

FIG. 2. Structure of HS1 teichoic acid-like capsule.

FIG. 3. 2D ^-'^P HMBC NMR spectrum of C. jejuni HS:l/44 teichoic acid CPS. This NMR spectrum shows the connections between the MeOPN moieties and positions 3 of the Fra units, and between the diester-phosphate and position 4 of Gal and position 1 of

Gro.

FIG. 4. GC-MS and NMR of C. jejuni HS44 CPS material. (A) GC-MS profile of the alditol acetate derivatives from the two CPSs of C. jejuni HS44, showing (i) the backbone units of the teichoic acid CPS, glycerol (Gro) and galactose (Gal), and (ii) those emanating from the second heptose-rich CPS, d-deoxy-S-O-Methyl-a/tru-heptose (6d-3O-Me-iu'/ro-Hep). 6-deoxy-ufrro-heptose (6d-a//ro-Hep) and 6-deoxy-galacto-heptose (6d-ga/-Hep), (B) ^SH NMR spectrum of HS44 CPS material showing the a-anomeric resonances emanating from 6d-afrro-Hep£ d-deoxy-gn/ncto-Hep/and 6d-3-0-Me-ofrroHep/of the heptose-rich CPS and from Gal of the teichoic acid CPS,

FIG. 5, Characterization of mutants in the HS1 CPS locus. A. Alcian blue stained

12,5% SDS PAGE of crude CPS preparations. Lane 1, Precision Plus protein standards; lane 2, HS1 wildtype; lane 3, HS1 1,08 mutant; lane 4, HS1 1,08 mutant complemented; lane 5, HS1 1.09 mutant; lane 6, HS1 1.09 mutant complemented; lane 7, HS1 wildtype. B. ³ⁱP NMR of CPS from HS1.08 complement; C. ^3SP NMR of CPS from HS1.09 complement; D. ³ⁱP NMR of CPS from HS1 wildtype.

FIG. 6. The GC-MS profile of the alditol acetate derivatives of C. jejuni CG2995 CPS,

FIG. 7. The Ή NMR spectrum of C. jejuni CG2995 CPS.

WO 2016/022412

PCT/US2015/043070

FIG. 8. (A) The 2D HSQC NMR spectrum of C. jejuni CG2995 CPS; (B) The

ID selective A NOEs of the C. jejuni CG 2995 CPS, Irradiated peaks are denoted with an Mixing time of 0.250 us was used.

FIG. 9. The ^3!P NMR spectrum of C. jejuni CG2995 CPS.

FIG. 10. The 2D ^!H-³ⁱP HMBC NMR spectrum of C. jejuni CG2995 CPS.

FIG. 11. Structure of HS5 CPS showing four variations: i) The main PS structure of C. jejuni CG2995, ii) variation 1, iii) variation 2_S and iv) variation 3.

FIG. 12. The GC-MS profile (top) of the alditol acetate derivatives of C. jejuni CG2995 CPS, following TEMPO oxidation that shows a reduction in abundance of the 3,6dideoxy-riho-heptose.

FIG. 13. TEMPO oxidation that shows a reduction in abundance of the 3,6-dideoxy-r/6e>heptose, indicating that its 07 primary' hydroxyl (free of MeOPN) is the site of preferred oxidation in this CPS, and that which will be mostly involved in the conjugation of C.

jejuni CG2995 CPS to carrier protein CRM197.

FIG. 14. Characterization of the FIS 1 conjugate vaccine. A. ³ⁱP NMR of HSIcpsCRMi97 conjugate vaccine showing the presence of MeOPN in the conjugate CPS. B,

Gel code blue stained 12% SDS-PAGE gel. Lane 1, CRMs??; lane 2, HSl-CRMj?7 conjugate. The mass of protein standards are shown on the left.

FIG. 15. NMR of HS:13 CPS. (A) ID ^!H NMR; and (B) ID ³ⁱP NMR spectra of C. jejuni 3019 CPS (serotype HS:I3).

FIG. 16, Linkage determination of MeOPN group by NMR. 2D ’H-³¹? HMBC NMR spectrum of C. jejuni BH-01-0142 CPS (A': 1,2,3-linked dd-afo-Hep/LD-.vfo-Hep with C residue; C: MeOPN).

WO 2016/022412

PCT/US2015/043070

FIG. 17. NMR analysis showing that non-sugar moiety was 3-hydroxypropanoyl, (A)

2D ^!H-ⁱ³C HMBC NMR spectrum of C. jejuni BH-01-0142 CPS (B^!: 1,3,4-Hnked Gai with residue D; (B) D: 3-hydroxypropanoyl group.

FIG. 18. ImmunogenicityofHSl-CRMi97 conjugate in mice. A. ELIS A liters to HS 1 BSA two weeks after three doses. B. Dot blot of C. jejuni cells immunodetected with mouse sera at a final dilution of 1:1000.

FIG, 19. Immune response to HS5-CRM397 conjugate. Mice were immunized with three (3) doses (10 pg and 50 pg by weight of conjugate) given at 4 week intervals. The mice were bled two weeks after the last doses.

FIG. 20. BH0142 (HS3) conjugate vaccine is immunogenic in mice. Data represent the mean (±SEM) reciprocal IgG endpoint titer per treatment group.

FIG, 21, Dot blot demonstrating immunogenicity of an HS1-CRM 197 vaccine. Purified capsules (1 mg/ml) were dot blotted in triplicate (2 ul each) to nitrocellulose and immunodetected with rabbit polyclonal antiserum to an HS1-CRM197 vaccine. HS1, wildtype HS1 capsule; HS1.08, capsule from a fructose transferase mutant of HS1 that lacks the fructose branch and the MeOPN; HS23/36, capsule from 81-176 which expresses a heterologous capsule (HS23/36).

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [0008] The tersn “polysaccharide antigen” as used herein refers to a capsule polysaccharide derived from Campylobacter jejuni (C. jejuni or Campylobacter jejuni} capsule. As used, herein, each polysaccharide antigen comprises a polysaccharide or

WO 2016/022412

PCT/US2015/043070 polysaccharide polymer derived from one C. jejuni strain. The inventive composition can be comprised of multiple polysaccharide antigens. As used herein, “polysaccharide” refers to two or more monosaccharide units composing a carbohydrate polymer molecule. A “polysaccharide polymer” refers to two or more polysaccharide molecules connected together. As used herein, “n” in the polysaccharide structure refers to the number of polysaccharide repeats in the polymer and is 1 or more and can be up to 100, [0009] An embodiment of the current invention comprises polysaccharide antigens comprising a polysaccharide or polysaccharide polymer derived from the capsule of a C. jejuni strain. The strains from which the capsule polysaccharides are isolated are selected from the group consisting of HS1, HS1/HS44, HS44, HS2, HS3, HS4, HS5, HS13, HS4/13/64, and HS50. A capsule polysaccharide polymer comprises 1 to 100 copies of a polysaccharide structure, derived from an individual C jejuni strain, connected together to form a polysaccharide polymer. The inventive immunogenic composition one or more polysaccharide antigens with each polysaccharide antigen comprising an isolated C. jejuni polysaccharide structure or polysaccharide polymer from a C. jejuni strain. The polysaccharides are isolated or purified away from lipooligosaccharide, or other structures associated with GBS or other autoimmune disorders.

[0010] A large number of the C. jejuni strains are identified, An embodiment of the current invention includes only capsule polysaccharides derived from C. jejuni strains, which have been shown to result in disease in humans.

<3

WO 2016/022412

PCT/US2015/043070

Example 1: HS1/HS44 and HS44 polysaccharide structure [0011] Vaccine strategies against C. jejuni have been largely limited due to the molecular mimicry between iipooligosaccharide (LOS ) cores of many strains of C. jejuni and human gangliosides (Moran, et at, J. Endotox. Res., 3: 521 (1996), This mimicry is thought to be a major factor in the strong association of C. jejuni infection with Guillain Barre Syndrome (GBS), a post-infectious polyneuropathy (Altos, J. Infect. Dis., 176(Suppl.): S125-128 (1997)). Thus, antibodies generated against LOS cores result in an autoimmune response to human neural tissue. It has been estimated that as many as 1/3000 cases of Campylobacter enteritis results in GBS. Therefore, the possibility of developing GBS could be associated with any whole cell vaccine against C. jejuni that includes ganglioside mimicry, [0012] Recent development of a molecular CPS typing system re-enforced the strong correlation betw'een CPS and Penner types (Poly, et al., J. Clin. Microbiol. 49: 1750 (2011)). Both Penner serotyping and molecular CPS typing have revealed the predominance of a handful of CPS types worldwide. Among CPS types, the HS1 complex is one of the most common, accounting for 8.2% of C. jejuni induced diarrhea worldwide ((Poly, et al., J, Clin. Microbiol. 49: 1750 (2011); Pike, et al., pIOs One 8: 607375 (2013)). This complex is composed of HS1 and HS44 types, and strains can serotype as HS1, HS44 or HS1/44. So far, only the CPS structure of the HS1 type strain has been described, which is composed of repeating units composed of 4-substituted a-D~ galactose (Gal) and glycerol (Gro) linked by phosphate (P) in a teichoic acid-like structure [-4)-a-D-Gal/>(l-2)-Gro-(l-P~]_n (Aspinall, et al., Eur. J. Biochem. 216: 880 (1993)). The HS1 CPS backbone may be decorated by β-D-fructofuranoses (Fru)

WO 2016/022412

PCT/US2015/043070 branches, at C-2 and C~3 of the Gal unit, which in turn may be decorated at 03 with MeOPN (Fig. 1; (McNally, et al., FEBS J. 272: 4407 (2005)). Both the fruetofuranose branches and MeOPN are found in non-stoiehiometrie amounts, presumably due to phase variation at homopolymeric tracts of bases in the genes encoding their respective transferases (McNally, et al., FEBS J. 272: 4407 (2005)). The -15 kb HS1 CPS locus encoding eleven genes for the synthesis of this polysaccharide (BX545859) is the smallest CPS locus identified to date in C. jejuni (Karlyshev, et al., Appl. Environ. Microbiol, 71: 4004 (2005))(Fig. 1).

[0013] The HS1 type strain used was MSC57360 and the HS44 strain (ATCC 43463) was obtained from the American Type Culture Collection (ATCC)(Manassas, VA). C. jejuni strain CG98-U-77 was isolated from a diarrhea ease from Thailand and was obtained from the Armed Forces Research Institute of Medical Sciences (AFRIMS). C.

jejuni strains were routinely cultured at 37°C under mieroaerobic conditions (5% O₂, 10% CO₂, and 85% N₂) on Mueller Hinton (MH) agar plates, supplemented with the appropriate antibiotic, if required. £. coli strains were grown in LB media supplemented with the appropriate antibiotics.

[0014] C. jejuni genomic DNA was extracted from 16 hour cultures. Sequencing of the CPS loci was performed as previously described (Karlyshev, et al., Mol. Microbiol. 55:

(2005); Poly, et al, J, Clin. Microbiol, 49: 1750 (2011);, Karlyshev, et ah, Gene 522:

(2013)).

[0015] The CPS was extracted from cells by hot water-phenol extraction for 2 hours at °C. The aqueous layer was dialyzed (1000 Da) against water followed by ultracentrifugation to separate the CPS from the LOS. The supernatant material

WO 2016/022412

PCT/US2015/043070 containing the CPS was subjected to size-exclusion chromatography (Sephadex G50) for further purification to yield the intact CPSs.

[0016] Determination of monosaccharide composition was performed using a procedure amenable to the alditol acetate method (Chen, et al., Carbohydr. Res. 343: 1034 (2008)) with the alditol acetates being analyzed in a ThermoFinnigan POLARIS™-Q (Thermo Fisher Scientific, Inc, Waltham, MA) gas chroraatograph/mass spectrometer (GC-'MS) using a DB-17 capillary column. The sugar linkage types were characterized by characterization of the permethylated alditol acetates by GC/MS as previously described (Chen, et ah, Carbohydr. Res. 343: 1034 (2008)). The NMR experiments were performed on a Broker 400 MHz spectrometer (Broker Corporation, Siberia, MA) equipped with a Bruker cryo platform at 295 K with deuterated trimethylsilyl propanoic acid and orthophosphoric acid as external standards.

[0017] The variable region containing the genes for synthesis of the polysaccharide are located between the conserved genes encoding the ABC transporter involved in capsule synthesis and assembly (FIG. 1), which also shows the variable region of the HS1 CPS locus (McNally, et ah, FEBS J. 272: 4407 (2005)). The DNA sequence of the capsule locus of the HS44 type strain contained homologs of 10 of the 11 genes found in HS1, missing only HS1.08, a gene of unknown function (FIG. 1). The gene content of HS44 capsule biosynthesis locus is summarized in Table 1. All shared homologs were >96% identical, except for the putative MeOPN transferase (HS44.07) which showed only 47% identity to that of HS 1, π

WO 2016/022412

PCT/US2015/043070

Table 1

Locus Tag	Putative function3	Relationship	identity with HS1&	Size (amino acid)
HS44.01	MeOPN biosynthesis	HS1.01	164/170 (96%)	170
HS44.02	MeOPN biosynthesis	HS1.02	252/253 (99%)	253
HS44.03	MeOPN biosynthesis	HS1.03	197/200 (98%)	200
HS44.04	MeOPN biosynthesis	HS1.04	775/779 (99%) 253/253	779
HS44.05	Methyl transferase	HS1.05	(100%)	253
HS44.06	Methyl transferase	HS1.06	255/257 (99%)	257
HS44.07	MeOPN transferase sugar-phosphate	HS1.07	308/642 (47%)	609
HS44.08	nucleotidyltransferase sedoheptulose 7-phosphate		*	224
HS44.09	isomerase D-glycero-D-manno-heptose 7-			201
HS44.10	phosphate kinase GDP-mannose 4,6-			360
HS44.11	dehydratase	-	-	343
HS44.12	GDP-fucose synthetase (fci)	-	-	381
HS44.13	GDP-fucose synthetase (fci)	-	-	385
HS44.14	CJ1429 like Nucleotide-sugar		o	310
HS44.15	epimerase/dehydratase Nucleotidyl-sugar pyranose	·		181
HS44.16	mutase			418
HS44.17	Heptosyi transferase CDP glycerol		1067/1095	1202
HS44.18	glycerophosphotransferase	HS1.09	(97%)	1100
HS44.19	Unknown Glycerol~3-phosphate	HS1.10	390/396 (98%)	397
HS44.20	cytidyiyltransferase	HS1.11	128/129 ^99%)	129

function attributed based on Biastp performed on non-redundant protein sequences database.

^Numbers in parenthesis are the percentage of identity between the H81 and HS44 proteins.

[0018] The HS44 locus included an insertion of 10 additional genes between HS1.07 and

HS1.09 encompassing 9,258 bp (Table 1, FIG. 1). These include 4 genes encoding

WO 2016/022412

PCT/US2015/043070 enzymes predicted to be involved in deoxyheptose biosynthesis (HS44.08 to HS44.11) and three genes (HS44.12, HS44.13 and HS44.15) encoding proteins that are homologous to epimerase reductases that have been recently demonstrated to be involved in 6-deoxyis/ira-heptose biosynthesis. The CPS locus of HS44 also includes a gene (HS44.14) similar to CJ 1429c coding for a protein of unknown function in NCTC 11168 (HS2), a nucleotidyl-sugar pyranose mutase (HS44.16) and a putative heptosyltansferase (HS44.17, Table 1 and FIG. 1). In contrast, the DNA sequence of the variable CPS locus of a clinical isolate that typed as HSI/44 was identical with that of the type strain of HS1. The minimum protein homology predicted from the 11 genes in these two capsule loci was >99%.

[0019] Fine structural analysis revealed that the polysaccharide structure of HS I/44 is similar to that of the previously described teichoic acid capsule polysaccharide (CPS) of

HS1 strain (Aspinall, McDonald et al. 1993, McNally, Jarrell et al, 2005): -»4)[MeOPN->3)”p-D-Fru~(l->]-a-Gal-(l->2)-Gro~(l-->P-> (FIG. 2).

[0020] FIG. 3 shows the phosphorous-proton connections detected in HSI/44 CPS that emanate from the linkages of the teiehoic-acid diester-phosphate (δρ 0.5 and 1.5) to position 1 of Gro and position 4 of Gal, and from the attachment of the MeOPN (δρ 14.3) to position 3 (δ_Η 4.83) of Fru residues. The H-4 resonance of the 4-linked Gal carrying the Fru branches appeared at δ 4.68, whereas that of the defructosylated 4-linked Gal resonated at δ 4.49 (FIG. 3). A similar pattern was observed for the H-l resonances of Gro. Simultaneous analysis of the HS1 type strain and HSI/44 CPSs, suggested that the HSI/44 CPS contained a lower degree of fructosylation, as judged by the lower

WO 2016/022412

PCT/US2015/043070 intensities of the 2,3,4-trisubstituted Gal linkage (GC-MS) and MeOPN resonance (³ⁱP [0(521] Analysis of HS44 CPS material identified two distinct polysaccharide capsule structures. One CPS was analogous to the aforementioned teichoie-acid CPS of HS1 and HS1/44 (FIG. 2), hut in which no MeOPN-containing Fru branches were observed. The second CPS was rich in heptoses, being composed of repeating blocks of 6-deoxygn/iicto-heptose (6d-gn/-Hep), ό-deoxy-n/riO-heptose (6d-afrro-Hep) and, in lesser amounts, 6-deoxy-3-O-methyl-n//rO“heptose (6d~n/teo~3-Q~Me--Hep/). The heptose configurations were characterized by comparison with well defined synthetic standards by GC. The linkage-type analysis (GC-MS) (FIG. 4A) revealed that the deoxy-heptoses were present in part as terminal and 2-substituted units in the furanose form.

[0022] Accompanying NMR studies (FIG. 4B) confirmed the presence of deoxy-heptoses (δ h 1.5 - 2.0) and revealed that these units were present in the a anomeric configuration (δ p 5.15 - 5.42). A new MeOPN moiety (δρ 14.0), different from that expressed by HS1 and HS1/44 was associated with HS44 CPS material. This is consistent with the divergence of the putative MeOPN transferase observed in this strain.

[0023] The product of the HS1.08 gene encodes a predicted protein of 849 amino acids, annotated as a putative sugar transferase (Karlysheev, et al., Mol. Microbiol. 55: 90 (2005)). Because the HS44 teichoic acid-like CPS lacked the non-stoichiometric fructose branch and the HS1.08 gene was missing from the capsule locus, we hypothesized that HS1.08 encoded a fructose transferase. A mutant in this gene expressed a lower MW capsule as on an Alcian blue stained gel and the MW was restored to that of wildtype in the complement as shown by gel; NMR analysis also confirmed complementation, hut

WO 2016/022412

PCT/US2015/043070 the lower intensity of the MeOPN resonance in the ^3!P NMR (FIG. 5B) suggested that complementation in this case was partial. Thus, HS1.08 appeal’s to encode a transferase that can transfer Fra to Gal.

[0024] Gene HS1.09 was annotated as a putative CDP glycerol transferase (Karlyshev et al., 2005). Mutation of this gene in HS1 resulted in the loss of CPS as detected by Aldan blue staining of an SDS-PAGE gel (Fig. 5A). Gel analysis of the complement of the mutant showed a faint CPS band (Fig. 5A), but restoration of CPS expression was confirmed by the ³ⁱP NMR spectrum which indicated the presence of MeOPN (Fig. 5B). [0025] In one embodiment an immunogenic composition, useful for inclusion in a vaccine composition against HS1, HS1/HS44 and HS44 C. jejuni strains, comprises polysaccharide antigen, comprising the structure;

[—»4)~a~D-Gal/?~( 1 -~»2)-Gro~( 1 3 2

Τ ΐ 2 2 [MeOPN]-*3)~Fru/ Fru/(3^[MeOPN], or a polymer comprising a repeating of the polysaccharide structure, wherein “n” is 1 to 100. The polysaccharide structure of HS44 comprises the above structure without “[MeOPN]“>3)~Fru/” unit connected at the 2 or 3 position of Gal. Therefore, in another embodiment, an immunogenic composition would comprise a polysaccharide antigen with a repeating polysaccharide structure, derived from HS44 that comprises the structure:

[-^4)-a-D-Gal/?-(l*2)-Gro-(l-*P--*]_n; wherein “n” is 1 to 100.

WO 2016/022412

PCT/US2015/043070

Campylobacter jejuni strain PG 3588 (HS:j):

[0026] Upon treatment of Campylobacter jejuni strain PG 3588 (HS:1) capsule polysaccharide (CPS) with mild acetic acid (5%), the fructose (Fru/) side branches and their accompanying MeOPN units were removed. The NMR of the defruetosyiated CPS showed the anomeric resonance at δ 5.21 that corresponds to the α-D-Gal residue (without the Fru/’ substitutions). H5 δ 4.18 was assigned from the H6 δ 3.75 proton resonance, Gro resonances were found to be at Hl/1'δ 4.05/4.12, H2 δ 3.98, and H3/3'

3.78/3.82.

[0027] All carbon resonances of Campylobacter jejuni strain PG 3588 (HS:1) capsule polysaccharide were assigned using a 2D TU 'C HSQC are summarized in Table 2, A 2D HMBC (Figure 4) showed a strong cross peak at (5h 4.54/ δρ 1.14), and (δπ 4,05, 4,11/ δρΐ.14) which confirmed the presence of the phosphodiester and its attachment to the Gro and to the C4 of Gal through a phosphodiester. Another resonance was detected in the 2D ⁵H-^3!P HMBC at δ 14,04 for a MeOPN moiety, and it showed a cross peak at δπ 3.75/δρ 14.04, identifying the attachement of MeOPN at the C-6 of Gal.

Table 2: Ή, °C chemical shifts of C/e/wni CPS PG 3588

Sugar residue	Hl/ΙΟΙ	H2 C2	H3/3' C3	H4 C4	H5 C5	H6/6- C6
a-D-Gal	5.21	3.88	3,90	4.54	4.18	3.75
	100,84	71.05	71.10	77.31	73,45	63.42
Gro	4,05/4.12 67,23	3.98 79,81	3.78/3,82 63.95

WO 2016/022412

PCT/US2015/043070

Example 2: HS5 derived polysaccharide structure [0028] One embodiment is an immunogenic composition against C. jejuni that contains an isolated capsule polysaccharide structure or polymers of the structure derived from HS5. The polysaccharide structure comprises four variants, with the structures as follows:

WO 2016/022412

PCT/US2015/043070 [MeOPN]*' κ 7 «-Bideoxy-Hep a 6 y i -> 7)a-DD~Ksp(t 3)Gl«citol(6 -+P-+ 2 2

T

1 c-Dideoxy-Hep e-Dideoxy-Hep [MeOPN]~ [MeOPN]-'[MeOPN]· !

s 7 a-Dideoxy-Hep i

a S x —» 7}a-BD~Hep( 1 —► 2)G5ucitol(6 -+P-+ ? ΐ a-Dideoxy-Hep s ΐ [MeOPN]-it ->· 7)«-BM-fcp(I -+ 2)Οΐ!ϊ«ΐο1ίδ^Ρ -+ 2 T t a-Bideoxy-Hep \

t [MeOPN]-'· tv -+ 7)a-DD~Hep( 1 -* 3}Ghiciioi(6 -+P-+ 2 2

T ΐ ¹ a-Dideoxy-Hep a-Dideoxy-Hep [MeOPN]'- IMeOPN][0029] Results from monosaccharide composition analysis revealed that the capsule polysaccharide (CPS) of strain CG2995 (HS:5) contained 3,6-dideoxy-riho-heptose, glucitol, and D-glycero-D~/?ia?wo-heptose (FIG. 6). Multiple linkages of each residue were observed; terminal 3,6-didcoxy-rihi3-heptose, 2,6-disubstituted Glucitol, 2,3,6trisubstituted Glucitol, 2-monosubstituted D-glyeero-D-wwnno-heptose, 2,6-disubstituted D-glyeero-D-ma/wio-heptose, 2,7-disubstituted D-glyeero-D-mnnno-heptose, and 2,6,7trisubstituted D-glycero-o-manno-heptose.

[0030] The 1D *Η NMR of the CPS revealed six anomeric peaks, three of which are associated with D-giycero-D-manno-heptose residues at 5.20 ppm, 5,18 ppm, and 5.16 ppm (A,B,C respectively), and 3 of which are associated with 3,6-dideoxy-riho-heptose residues at 5.21 ppm, 4,96 ppm, and 4.87 ppm (K,L,N respectively) (FIG. 7). Linkages and ring resonances were then confirmed via 2D *Η~Ή COSY, TOCSY, and NOESY

WO 2016/022412

PCT/US2015/043070 experiments. Linkages found through NMR experiments coincided with the linkages assigned by GC-MS.

[0031] With the aid of 2D HSQC and HMBC the Glucitol residues (Χ,Υ,Ζ) could are assigned, along with the ring region resonances from the six heptose residues. As expected carbons involved in the glycosidic linkages, C2 (δ 78.1) of the D-glycero-Dmanno-heptose A, B and C, C6 (δ 76.8) of D-glycero-D-mmwo-heptose A, C2 (δ 81.6) of Glucitol Y and Z, C2 (δ 82.5) of Glucitol X, and C3 (δ 78.8) of Glucitol Y and Z, were found to be down-field resonances (FIG. 8 (A)). The deoxy resonances associated with the 3,6-dideoxy~ri&o-heptose were easily observed at δ 37.1 (C3) and δ 36.1 (C6). Selective ID nOe experiments (FIG. 8(B)) also showed the presence of the linkages aforementioned.

[0032] The ID ³ⁱP and 2D ^!P HMBC NMR revealed resonances at 0.96 and 1.30 ppm, indicating that the capsular polysaccharide repeats were linked with a phosphate bridge (FIG. 9). This bridge links through the 6-position of the Glucitol and the 7position of the D-giycero-D~»n«no~heptose (Fig. 9). The ID ³ⁱP spectra also gave rise to a peak δ 14,5 indicating MeOPN, and through the 2D ⁱH-³ⁱP HMBC the MeOPN could be linked to being a 7-subsituted 3,6~dideoxy~ribo-heptose (FIG. 10).

[0033] One main capsular polysaccharide was observed with a backbone of [-7)-a-oglycero~D-mnn«o-heptose-(l-3)~GlucitoI-(6-)-P-] with 2,6-disubstiiution of the D-glyceroD-mmwm-heptose, and 2~monosubstitution of the Glucitol with a~3,6-dideoxy-ri&£?~ heptose (FIG. Hi), Three other variations of the capsular polysaccharide repeat were also noted; variation 1 with 2-monosubstituted D-glyeero-D-muuno-heptose and Glucitol linked through the 2-position instead of 3 to D-glycero-D-mnnno-heptose (FIG. 1 lit),

WO 2016/022412

PCT/US2015/043070 variation 2 with 2,6-disubstitution of the D-glyeero-D-munno-heptose and Glucitol linked through the 2-position instead of 3 to n-gb/cero-o onanHo-heptose (FIG. 11 iii), and variation 3 with 2-monosubstituted D-gSycero-D-mmwo-heptose and 2-monosubstituted

Glucitol (FIG. 1 liv).

Example 3: Conjugation of CPS polysaccharide to protein carrier [0034] One or more polysaccharides or polysaccharide polymers can be conjugated to a carrier molecule to improve immunity. The carrier, in one embodiment, is a protein carrier molecule. As an example protein carrier, CRMjg? can be conjugated to the polysaccharide or polysaccharide polymer. The GC-MS profile of the alditol acetate derivatives of C. jejuni CG2995 CPS, following TEMPO oxidation is shown in FIG. 12, Conjugation is illustrated in FIG. 13.

Conjugation of HS5 polysaccharide [0035] Isolated C. jejuni HS5 polysaccacharide was conjugated to a protein structure and is described here as an illustration of conjugation of the polysaccharide or polysaccharide polymers. The overall scheme for conjugation is illustrated in FIG. 13. Any protein carrier is envisioned to be conjugated. Furthermore, conjugation to a protein carrier can be by any number of means.

[0036] As an illustrative example, in FIG. 13 the polysaccharide was conjugated to

CRM :97 by TEMPO-mediated oxidation. In this method, as shown in FIG. 13, the first step is oxidation of approximately 10% of the plrimary hydroxyls of the intat CPs to carboxylic acids via TEMPO-mediated oxidation. The scheme in FIG. 13 illustrates

WO 2016/022412

PCT/US2015/043070 conjugation using the primary hydroxyl of the DD-Hep as one of the sites of oxidation. Non-stoichiometric oxidation may also occur at C-6 of Glc and at the C1V~OH of the side-chain substituent. Following activation of the CPS, conjugation to the carrier protein (e.g., CRMs97) is accomplished, in the TEMPO-mediated method shown in FIG. 13, through carbodiimide coupling. Visualization of conjnation is by any means, such as gel electrophoresis.

Conjugation of HSI polysaccharide [0037] A glycoconjugate composed of HS I teichoic acid CPS and the protein carrier CRM197 was created through a conjugation scheme, similar to that used for HSS, based on stoichiometric oxidation of 10% of the available primary hydroxyls in the CPS. After oxidation of primary hydroxyls, the activated HSI CPS was then conjugated to CRM· 97 by carbodiimide-type coupling of the newly created carboxylic acid functionalities in the CPS and exposed CRM^? lysine units. Importantly, analysis of the HS I CPS-CRMi?? conjugate vaccine by NMR confirmed that the MeOPN and phosphate moieties remained intact during the conjugation manipulations. These results are shown in FIG. 14, A comparison of the intensities of the anomeric resonances in the partially oxidized HSI CPS indicated that half of the backbone Gal residues were branched by the Fru-cntaining

MeOPN units.

Example 4: Polysaccharides in HS complexes [0038] Polysaccharide structures were identified in C. jejuni Penner serotype complexes. For example, anfi-HS4 serum results in cross-reaction to other strains strains

WO 2016/022412

PCT/US2015/043070 of the HS4 complex, including HS13, HS4/13/64 and HS50 capsules, Isolation and analysis of the polysaccharides from these strains resulted in identification of dissacharides containing a common ido-heptose unit. The strains and isolated polysaccharide derived from the strains are listed in Table 3.

Serotype Structure | /Strain |

Table 3: HS4 complex capsule polysaccharide structures

HS4 type strain	~-»3)~L-p-Diifo“Hep“(i-~*4)~p~D~GkNAc-Cl--> (non-stoichiometric MeOPN at C~4 of LD-Zdo-Hep)
HS13	-*3)-6d~p~»~i A?-Hep-( 1 ~>4)-β-»~Ο1ε-(1 (50%) (non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-/ifo-Hep); and/or —>3)“L”p”D“/<fo-H6p~tl—*4)“P“D-G1c~(1-» s 50%)
HS4,13,64 (e.g., strain CG8486)	->3)-6d-p-D-/do~Hep-(1^4j-p~n~GIsNAe-(l^ (80%) (non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-/ifo-Hep); and/or ...->3)-L-p-D-/i/!?-Hep-(I->4)-p-U-Gk'NAc-(l--i (20%) (non-stoichiometric MeOPN at C-2 of LD-/ifo-Hep)
HSSG	-^3)-L-p-D-iifo-Hep-(l-->4)-p-D-GIc-(l--> (85%) (non-stoichiometric MeOPN at C-4 of LD-Zifo-Hep); and/or -*3)-6d-p-D-iWe-Hep-(l->4>p-D-Glc-(l-> (15%) (non-stoichiometric MeOPN at C-7 of 6d-ido-Hep)

[0039] Illustrated in Table 3, the common, surprising feature of these isolated capsule polysaccharides is the ido-heptose unit. As such, an embodiment is an immunogenic composition comprising one or more polysaccharide antigens, each comprising polysaccharide structures derived from these strains of C. jejuni.

[0040] The previously described CPS structure of C. jejuni strain CG8486 (HS: 4:13:64)

WO 2016/022412

PCT/US2015/043070 consisted mainly of a disaceharide repeating unit [~»3)-όά-β-Ο-ζΙ/σ-Ηβρ-(1~»4)~βGleNAe~(l—»], with non-stoiehiometric O~methyl phosphoramidate substituent attached to C-2 and C-7 positions of zrfo-heptose. A minor component of L-gfycero-D-zifc-heptose (LD-zWo-Hep) was detected by GLC-MS, using alditol acetate derivatives for compositional analysis and permethylated alditol acetate derivates for lingage analysis of, and was newly found in this strain. The sugar ring configuration of 6-deoxy-heptose and L-g/ycero-D-heptose were assigned as idose. The traces of 1,7-an.hydro-L-g/yeero-D-htoheptose (1,7-anhydro-LD-zWo-Hep) and l,6-anhydro-L-gfycero-D-z<io-heptose (1,6anhydro-LD-zWo-Hep) originated from LD-zWo-Hep during acid hydrolysis.

[0041] In addition to previously reported linkage types in C. jejuni CG8486 CPS (3substistuted dd-z'ifc-heptose [-->3)-6d-ido-Hep-(l--»] and 2,3-di-substistuted 6d-zrioheptose [~->2,3)-6d-z'ifo-Hep-(l-->j, 3,7-di-substistuted 6d-zrfo-heptose [-+3,7)-6d-zrioHep-(I-»], 4-substituted N-acelyl-glueosamine [-»4)-GleNAc~(!—>]), the GLC profile of

GLC-MS of permethylated alditol acetate derivatives of C.jejimi HS:4:13:64 CPS showed two additional linkage types from LD-too-Hep which were not detected in previously reported structure, including 3-substistuted L-gfycero-D-zzfc-heptose [~>3)-LDzifo-Hep~(l—»] and 2,3-di-substistuted L-gfycero-D-zrio-heptose [-->2,3)-LD-zrio-Hep~ (1->1.

[0042] The ID ^!H NMR of C. jejuni CG8486 CPS showed two resonances of two β[0043] glycosides at δ 4.94 and δ 4.66 which were nd-hto-Hep/LD-iao-Hep and GlcNAc, respectively. The presence of two anomeric proton resonances for three monosaccharide residues (6d-z'£o-Hep, LD-zrfo-Hep, and GlcN Ac) suggested that both 6d-z2/o~Hep and LDz’ifo-Hep may contain the same chemical shifts through the sugar ring system except the

WO 2016/022412

PCT/US2015/043070

H-6 position since the only difference between them was at the C-6 position with or without a hydroxyl group. The ^!H NMR spectrum also revealed one methyl singlet at δ 2.07 which was characteristic of the TV-acetyl moiety from GlcNAc and methylene signals at δ 1.77 and δ 2.03 which were 6-deoxy-moiety from 6d~/sfo~Hep. In addition, ID ^jiP NMR detected a characteristic MeOPN signal at δρ 14.7, it was determined that the CPS of C. jejuni serotype HS4:13:64 (see Table 3) contained both 6-d-ido-Hep and LDido-Ηερ within its CPS:

[—>3)-6d-p~/ifo-Hep-(i-H>4)-p-GlcNAc-(l“>] (with non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-ido-Hep) as a major repeat; and [~>3)-LD~P-z</o-Hep-(l-»4)-P-GleNAc-(l->] (with non-stoichiometric MeOPN at C2 of LD-ido-Hep) as a minor repeat.

CPS determination of C. jejuni HS:4 Type Strain (Strain MK7) [0044] The CPS isolated from C. jejuni strain MK7 (HS4) was composed of L-g/ycero-Dfifo-heptose (L.D-fori-Hep) and /V-acetyl-glucosamine (GlcNAc) by GC-MS profile determination of alditol acetate derivatives. The above CPS composition of C. jejuni HS:4 type strain was similar to previously reported CPS of serotype HS:4 complex (HS:4,13,64; strain CG8486), which contains mostly ό-deoxy-hfo-heptose (6d-/Jo-Hep) instead of LD-Zrio-Hep. GC-MS of permethylated alditol acetate derivatives showed the following linkage types of each monosaccharide: 3-substituted L-g/yccro-D-fo’o-heptose [-~>3)-LD~j£fe~Hep-(l —>] and 4-substituted V-acetyl glucosamine [™>4)-GlcNAc-(l~>].

[0045] The *H NMR spectrum of the C. jejuni strain MK7 (type strain HS:4) CPS

WO 2016/022412

PCT/US2015/043070 showed two β-anomerie proton resonances at δ 4.70 and δ 4.94 for GlcNAc and LD-ZdoHep, respectively. The ³H NMR spectrum also revealed one methyl singlet at δ 2.07 which was characteristic of the A-aeetyl moiety from GlcNAc and a broad range of overlapping sugar ring proton resonances between δ 3.50 and δ 4.55. In addition, ID ³ⁱP

NMR detected a weak trace of MeOPN signals at δρ 14.3. The substituted sites of

MeOPN could not be detected due to the small amount of MeOPN substitution in this

HS:4 type strain.

CPS determination of C. jejuni C. jejuni Serotype HS:13 (Strain MK16) [0046] C. jejuni HS4 type-strain (MK7) contains a CPS composed of the following disaccharide repeat: [>3)-L-P-D”Kfo-Hep-(l—->4)~p-G!cNAc~(l--»]. The monosaccharide composition analysis, using GC-MS of alditol acetate derivatives of C. jejuni strain MK.16 (serotype HS:13) revealed the presence of glucose (Glc), 6-deoxy-Zi/o-heptose (6d-fifo-Hep), and L-gfyeero-D-mri-heptose (LD-Zrio-Hep) by GS-MS determinationof alditol acetate derivative profiles. Linkage analysis of profdes of permethylated alditol acetate derivatives showed that these units were present as 4substituted glucose [~-»4)~Glc~(l~-»], 3-substituted 6-dcoxy-Zrio-heptose [-->3)-6d-hfo··

Hep-(l—>], 2,3-di-substituted 6-deoxy-Zdo-heptose [™>2,3)-6d-Zi/o-Hep-(l-+], 3substituted L-gfycero-D-Zifc-heptose [-->3)-LD-Z£/o-Hep-(l-4·], and 3,7-di-substituted 6deoxy-irio-heptose [-->3,7)-6d-;ifo-Hep-(l In addition, a small amount of terminal glucose [Glc-(1--»] was detected as the non-reducing end of the CPS. C. jejuni serotype

HS:13 contains 4-substituted Glc as backbone instead of 4-substituted GlcNAc (seen in

WO 2016/022412

PCT/US2015/043070 [0047] The Ή NMR spectrum of C. jejuni serotype HS:13 CPS showed two β-anomeric proton resonances at δ 4.63 and δ 4.92 which assigned as Glc and 6d-fi/o-Hep/ LD-frfoHep, respectively (Fig. ISA). The ^!H NMR spectrum also revealed the methylene signals (multiplet) at δ 1.86 and δ 2,00 which were characteristic of the 6-deoxy moiety from 6dkfe-Hep and a broad range of overlapping sugar ring proton resonances between δ 3.30 and δ 4.55. ID ^jiP NMR detected two resonances at δρ 14.1 and Sp 14.4 which were typical of MeOPN signals (Fig. 15B).

[0048] It was determined that C. jejuni strain MK16 (serotype HS:13) CPS consists of the following disaccharide repeats in quasi equal concentrations (with MeOPN nonstoichionietrically attached to C-2 and C-7 of 6d-$~ififc>~Hep):

[~+3)~0d-3-D~Kfo-Hep-(1 ~~>4)~P-G!c-(I --->]; and [—>3 )-L· β -Drii/o -Hep-( 1 —>4)’3GlC( 1 —>].

C, jejuni serotype HS3/13/50 [0049] HS: 3:13:50 complex has been identified predicated on a quantitatively low level immune-crossreactivity. C. jejuni strain BH-01--0142 (serotype HS: 3:13:50) was composed of galactose (Gal), 6-deoxy-ii/o-heptose (6d~fi/o~Hep), and L-glycero-O-idoheptose (LD-lifo-Hep) using GS-MS using alditol acetate derivative profile determination for compositional analysis of C. jejuni BH-01-0142 CPS (serotype HS:3:13:50)).

[0050] The sugar linkage types: 4-substituted galactose [—»4)-Gal-(l -->], 3-suhstituted 6deoxy-heptose [~>3)-6d-Hep-(l—>] and 3-substituted L-g/ycero-D-Zifc-heptose [--+3 )-1,0£ifo~Hep-(l-»] were found to make up the CPS of serotype HS:3:13:50. using GC-MS

WO 2016/022412

PCT/US2015/043070 profile analysis of permethylated alditol acetate derivatives of C. jejuni BH-01-0142 CPS (serotype (HS: 3:13:50)). In addition, minor components, 3,4-di-subslituted galactose [-~>3,4)~Gal~(l-~>], 2,3-di-substitoted 6-deoxy-heptose [-»2,3)~6d-Hep~(l-»], and 2,3-01substituted L-g/ycero-D-z'ffc-heptose [~->2,3)-LD-/£fo-Hep~(l---»] were also characterized.

The above results suggested that the backbone units of C. jejuni serotype HS: 3,13,50

CPS were [--»4)-GaI-(l-~>], [-»3)-6d~Hep-(l->], and [->3)~LD~/Jo~Hep-(!-->], with three other non-sugar components were non-stoichiometrically attached to the C-3 of Gal, and

C-2 of 6d-/rio-Hep and LD-frio-Hep, Also, a terminal Gal [Gal-( 1 -—>] was also determined and was suggested as a non-reducing end.

[0051] The ^SH NMR spectrum of the C. jejuni serotype HS:3:13:50 CPS showed broad overlapping peaks between δ 5.00 ppm and δ 5,30 ppm representing the anomerie proton signals. These overlapping peaks suggested the presence of α-anomeric sugars. In addition, the ^SH NMR spectrum also revealed a methylene signal at δ 1.80 and δ 2.02 which are characteristic of 6~deoxy moiety from 6d-ri/o-Hep, Another proton resonance at δ 2.72 was later confirmed as a methylene signal which also revealed in the ^!H NMR spectrum.

[0052] In order to obtain the information for the non-sugar component, ^3,P NMR of the C. jejuni BH-01-0142 CPS was performed to determine any phosphorus substituents. The phosphorus resonances at δρ 15.3 revealed the presence of an O-methyl phosphoramidate groups (MeOPN) or CH3OP(O)NH2(OR), which was involved in the structural moiety in the serotype HS:3,13,50 of C. jejuni CPS. The appearance of one MeOPN signal suggested this unique component was partially attached to one of the monosaccharide residues in the CPS of C. jejuni strain BH-01-0142, since the results of sugar linkage type

WO 2016/022412

PCT/US2015/043070 analysis revealed the presence of minor component of 1,3,4-linked Gal, 1,2,3-linked 6d/f/o-Hep and 1,2,3-linked LD-fdo-Hep, [0053] 2D ^lH-³ⁱP HMBC NMR of C. jejuni BH-01-0142 CPS was carried out to elucidate the linkage site of the MeOPN group (FIG, 16). The cross-peak at δρ 15.3/δπ 3.78 represented the correlation between the phosphorus and the methyl group of the MeOPN, A strong proton-phosphorus correlation between δρ 15.3 and δh 4.56 suggested the linkage site of the MeOPN group, with also a weak proton-phosphorus correlation between δρ 15.3 and the anomeric proton at δπ 5.10. Thus, the combination of the results from monosaccharide linkage type analysis and 2D HMBC NMR showed that the D-methyl-phosphoramidate group (residue C) was attached to the C-2 position of 6d-irioHep and LD-i'do-Hep (residue A').

[0054] A 2D ^!H-ⁱ³C HMBC NMR experiment (FIG. 17) showed that a second nonsugar moiety was that of 3-hydroxypropanoyl. The cross-peaks at δπ 3.89¾ 173.0 and

2.72¾ 173.0 showed three-bond and two-bond connectivities of the carbonyl ester ΟΙ with H-3 and H~2 of 3-hydroxypropanovl group (residue D), respectively. The 3hydroxypropanoyl group was observed to be connected to the C-3 of Gal, by interpreting the cross-peak at 5.20.¾ 173.0, and also by taking into account the results from linkage type analysis that showed a minor peak of 1,3,4-linked Gal, [0055] We determined that C. jejuni serotype HS:3 has a CPS with the disaceharide repeat (with non~stoiehiometrie substitutions of O-methyl phosphoramidate at C-2 of 6d-a-fJo-Hep/L-a~D-hfo~Hep and 3-hydroxypropanoyl ester at C-3 of a-Gal):

[-A3)L-a-D-iife-Hep-(l~->4)-a-Gal-(land

WO 2016/022412

PCT/US2015/043070 [->3)- 6d-a~/ifc~Hep-( 1 ->4)-a-Gal-( 1 ->].

Example 5: Immunogenic composition [0056] An immunogenic composition against C. jejuni is can comprise one or more isolated C. jejuni polysaccharides or polysaccharide polymers. The composition contains the polysaccharides or polysaccharide polymers free of LOS, which is associated with Guillain-Barre Syndrome, An embodiment is a composition comprising one or more isolated C. jejuni derived polysaccharides or polysaccharide polymers, with the polysaccharide polymer comprising 1 to 100 polysaccharides linked together (i.e., “n” greater than or equal to 1). The structures of the isolated C, jejuni polysaccharide are derived from one or more of the strains HS5, HS1, HS2, HS3, HS4, HS4/13/64, HS50 and HS13.

[0057] In one embodiment, the composition comprises one or more polysaccharide structures selected from the group consisting of:

[MeOPN]”·

I &

7)«£-DD-Hep{ 1 —* 3)GlwitoI( 6 —* P-~* ffi-Dsdeoxy-Hep a-Dsdesxy-Hep [MeOPN]”·

T [MeOPN]29

WO 2016/022412

PCT/US2015/043070 [MeOW

7)a-DD-Hep(l 2)Glucitol(6 s-Dideoxy-Hep [MeOPN]’ .

-» 7)a~DD»Hep( 1 —»2)Giucitoi{6 ->?-* a-Didessy-Hep [MeOPN]- .

7>DE5-HepCl —· 3)GfosM(6-»,P -* e*Dideoxy~Hep [MeOPN]“«-Dideoxy-Hep

T (MeOPN]*[—>4)„_a„D”Gaip-(l—>2)-Gro-(l—>P—*]„, derived from C, jejuni strain HS44; and [—>4)-a~D-Gaip-( 1 —>2)Gro~( 1 —~>P—->] _n 3 2 ’ ΐ T 1 i [MeOPN]~*3)~Fruf Fru/-(3<-[MeOPN], derived from C. jejuni strain HS1 and/or

HS1/44;

[-~*3)-L-P-D-ido-Hep-(l”>4)-P”D-GlcNAc-(l—*]_n, derived from C. jejuni strain

WO 2016/022412

PCT/US2015/043070

HS4/HS13/HS64, with non-stoichiometric substitution of O-methyS-phosphoramidate at position 2 of L-D-ido-heptose;

[—>3)-6d-p-D-ido-Hep-(l--»4)-P-D-GlcNAc-(l—*]_n, derived from C. jejuni strain

HS4/13/64, with non-stoichiometric MeOPN at C-2 and/or C-7 of dd-ido-Hep;

[™-»3)~L~P~D~ido~Hep-(l ~~»4)~P-D~GleNAe-(lderived from C. jejuni strain HS4, with non-stoichiometric MeOPN at C-4 of LD-ido-Hep;

[—>3-6d-p-D-ido~Hep-(l-->4)-p-D-Glc-(l —·»]„, derived from C. jejuni strain HS13, without MeOPN or with non-stoichiometric MeOPN at C-2 and/or C-7 of dd-ido-Hep;

(3,6,-O-Me)-D-glycero-a-L~gic-Hepp ' 1 i

[-~>2)-P-D-Rib/'-(l -*5)-P-D-Gal/NAc-( 1 ~->4-a-D-GlcpA6-( 1 —»] _n ' 3 5 ΐ ΐ

MeOPN] [NGro/Etn], whererin NGro ^:::: aminoglycerol; Etn = ethanolamine, derived from HS2;

[--»3)-L-alpha-D-ido-Hep-(l->4)-alpha-Gal~(l—»]„, derived from C. jejuni strain HS3, with non-stoichionroetric substitution O-methyl-phosphoramidate at position 2 of ddeoxy-alpha-D-ido-heptose with or without a 3-hdroxypropanoyl ester at C-3 of a-Gal;

WO 2016/022412

PCT/US2015/043070 [—>3)-L-P-D-ido-Hep-(l—>4)”P~D-Glc-(1—derived from HS50, with nonstoichiometric MeOPN at C-4 of LD-ido-Hep;

and [—»3-0d“P~D~id0”Hep-(l-~-*4)-P-D-Gle-(iderived from C. jejuni strain HS50, with non-stoichiometrie MeOPN at C-7 of 6d-ido-Hep, wherein the same polysaccharide is linked to form a polysaccharide polymer comprising 1 to 100 polysaccharides linked together (i.e., “n” greater than or equal to I), [0058] The polysaccharides or polysaccharide polymers of the decomposition can be linked to a carrier, wherein said carrier can be a protein. In one embodiment, the protein carrier is CRM197.

Example 6: Induction of immune response by CPS conjugates.

Induction of immune response against HSL HS1/HS44 and HS44 [0059] In one embodiment an immunogenic composition, useful for inclusion in a vaccine composition against HS1, HS1/HS44 and HS44 C. jejuni strains, comprises a polysaccharide, comprising the structure:

[~H‘4)-a-D-Galp-( 1 —*2)-Gro-( 1 3 2 ' ί ΐ 1 1 [MeOPN]-->3)~Fru/’ Fruf-(3*~[MeOPN],

WO 2016/022412

PCT/US2015/043070 or a polymer comprising a repeating of the polysaccharide structure, where “n”. In an alternative embodiment, the immunogenic composition can comprise the HS44 composition, as in Example 1, which does not contain the “[MeOPN]—>3)-Fru/“ unit. [0060] Surprisingly, the above structure found in HS1 and HS1/HS44 strains induces an immune response against HS44 strains. In the study, mice were immunized with escalating amounts of vaccine administered with Alhydrogel® (Clifton, NJ), Two weeks following the final immunization, all immunized animals exhibited significant levels of serum IgG antibodies specific against HS1 CPS (P<0.05) compared to pre-immune sera. Furthermore, this effect was dose dependent as mice immunized with 50 pg of vaccine (by weight) per dose had a significantly higher endpoint titer (P<0.05) than mice receiving 10 pg per dose. These results illustrate that HS1 is capable of generating high levels of anti-CPS antibodies in mice. The results of these studies is illustrated in FIG.

18. Also, shown in FIG. 19, a dot blot demonstrating immunogenicity of an HS1CRM197 vaccine. Purified capsules (1 mg/ml) were dot blotted in triplicate (2 ul each) to nitrocellulose and immunodetected with rabbit polyclonal antiserum to an HS1-CRMI97 vaccine. HS1, wildtype HS1 capsule; HS1.08, capsule from a fructose transferase mutant of HS1 that lacks the fructose branch and the MeOPN; HS23/36, capsule from 81-176 which expresses a heterologous capsule (HS23/36),

Induction of an immune response using an HS~5 polysaccharide composition [0061] The ability of isolated HS5 polysacccharide to induce an immune response was evaluated. It is contemplated that isolated HS5 polysaccharide could be used conjugated

WO 2016/022412

PCT/US2015/043070 to any of a number of protein carriers. However, as an illustration, CRMj97-conjugated HS5 polysaccharide was evaluated.

[0062] In this study. HS5 was conjugated to CRMj97 predicated on the method in Example 3. BALB/c mice were given three doses each of 10 pg or 50 pg of HS5 polysaccharide-conjugate at 4 week intervals, with 200 pg of ALHYDROGEL® (Brenntag AG, Germany). The mice received a total of three injections. Two weeks after the last dose, the mice were bled and the sera evaluated by ELISA, The results of this study are shown in FIG, 19 showing CPS-speeifie IgG responses.

[0063] The immune response of HS3 conjugated to CRM|97 was also examined. Female BALB/c mice were immunized via subcutaneous injection with conjugate vaccine (HS3 from BH0142 conjugated to CRM197) in aluminum hydroxide 3 times at 4-week intervals. Vaccine was given by weight. A dose of 5 pg corresponded to approximately 0.5 pg of conjugated polysaccharide and a dose of 25 pg corresponded to approximately 2.5 pg of conjugated polysaccharide. Serum was collected 2-weeks following each immunization. Capsule-specific IgG responses were determined by ELISA. The results are shown in

FIG. 20.

[0064] Additionally, the immune cross-reactions among members of the HS4 complex were evaluated. In these studies, whole cell proteinase K digested samples of various members of the HS4 complex were electrophoresed on 12.5% SDS-PAGE gels and immunoblotted with rabbit polyclonal antisera made against formalin killed whole cells of members of the HS4 complex. HS4 anti-serum was found to cross react to HS13 and

HS4. Anti-HS4/13/64 serum was found to crossreaet with HS64 and HS4 and to a small extent to HS50,

WO 2016/022412

PCT/US2015/043070 [0065] In similar studies, rabbit anti-HS13 serum was found to cross react with HS4 and

HS13 and anti~HS64 serum was found to cross react with HS4, HS13. HS4/13/64 and

HS50, Similarly, rabbit polyclonal antiserum made to conjugate vaccine composed of the capsule of HS4/13/64 strain conjugated to CRM 397 was used in an immunoblot to determine the cross reactivity of the vaccine to proteinase K digested whole cell preparations of other members of the HS4 complex. Antibodies to the vaccine crossreacted to HS4 and HS64, but not to HSI3 or HS50,

Example 7: Method for inducing an anti-C. jejuni immune response in mammals [0066] An embodiment of the invention is the induction of an immune response against capsule polysaccharide. The embodied method comprising administering an immunogenic composition comprising one or more polysaccharide antigens, wherein each polysaccharide antigen comprises a C. jejuni capsule polysaccharide polymer. The Campylobacter jejuni capsule polysaccharide polymers comprise of C. jejuni strains, as in Examples 1-4. As such, a capsule polysaccharide polymer comprises 1 to 100 copies of a polysaccharide structure, derived from an individual C. jejuni strain, connected together to form a polysaccharide polymer, induction of immunity can be against one or more strains of C. jejuni.

[0067] The capsule polysaccharide are derived from one or more C. jejuni strains selected from the group consisting of HSI and HSI complex (HSI, HS1/HS44 or HS44), HS2, HS3, HS4, HSS, HSU, HS4/13/64, and HS50. The inventive immunogenic compositions would comprise isolated C. jejuni polysaccharide structures or polysaccharide polymers of the structures, without lipooligosaecharide, or other

WO 2016/022412

PCT/US2015/043070 structures associated with GBS, The polysaccharide polymers can he conjugated or unconjugated to a carrier molecule and the composition administered at a dose range of 0.1 pg to 10 mg per dose with or without an adjuvant.

[0068] Another embodiment is a method of to induce an immune response against C. jejuni by administering isolated C. jejuni capsule polysaccharide derived from HS1, HS1/HS44 or HS44, In the inventive method, the composition is used to induce an immune response against HSi, HS1/HS44 or HS44, As an example, a composition comprising isolated C. jejuni capsule polysaccharide, isolated away from or purified from LOS components and other components that can cause autoimmune responses such as Guillain-Barre syndrome, such as derived from HSI, are used to induce an immune response against HSI, HS1/HS44 and HS44 C. jejuni strains.

[0069] In another embodiment, a composition comprising one or more of the polysaccharide comprising one or more of polysaccharides derived from HS4, HSI 3, HS4/HS13/HS64 or HS50 can be used in a method to induce immunity against any of the C. jejuni strains of the HS4 complex, comprising HS4, HSI 3, HS4/HS13/H64 or HS50. [0070] In the above described compositions, the polysaccharides or polysaccharide polymers can be linked to a carrier, wherein said carrier can be a protein. In one embodiment, the protein carrier is CRM 597.

[0071] As an example, the embodiment method, comprises the steps:

a. administering an immunogenic composition comprising one or more C. jejuni isolated capsule polysaccharide polymers derived from capsules of C. jejuni strains selected from the group consisting of: HSI and HSI complex (HSI, HS1/HS44 or HS44), HS2, HS3, HS4, HS5, HSI3, HS4/13/64, and HS50, wherein capsule

WO 2016/022412

PCT/US2015/043070 polysaccharides of a strain can be linked to form a polysaccharide polymer comprises 1 to 100 copies of a polysaccharide structure, derived from an indi vidual C. jejuni strain, connected together to form a polymer and wherein said composition would comprise isolated C. jejuni polysaccharide structures or polymers of the structures, without lipooligosaccharide, or other structures associated with GBS and wherein the polysaccharide or polysaccharide polymers can he conjugated or unconjugated to a carrier molecule and the composition administered at a dose range of 0.1 pg to 10 mg per dose with or without an adjuvant, and wherein the polysaccharide structures include one or more ofthe following structures selected from the group consisting of:

[MeGPN]~7 e'Did^esy-Hep

6 > 7)®-DD-Hep(l 3)Gtoeitol(6 -*P2 2 f f

1 a-Didaoxy-Hep a-Dideoxy-Hep 7 7

T I [MeOPN]”· [MeOPN]”'· tMeOPNJ*!

a-Did|0xyHgp

-»7}e~DI>HepO 2)Gksei?al(6 P 2 ί

α-Dsdeosy-Hep t

EMeOPN]*·

WO 2016/022412

PCT/US2015/043070 —»7)®-DD~Hep( I —» 2)G5ticsiol(<5 P —» 2 t s~Dideoxy»Hep

EMeOPHT!

i a-Dsdeoxy-Hep ΐ

[MeOPN]~3)©μΜ(6~-»Ρ“ t

«<Bid«&xy-Kep

T pvteOPN]·· [™>4)-a-D~Gal/5-(l-->2)~Gro-(l*P™i>]_n, derived from the derived from the C. jejuni strain HS44;

[™»4)-a-D~Galp-( 1 ->2)~Gro-( 1 -»P.....>]„

2 τ t

1 [MeOPN]-^3)-Fruf Fru/-(3^[MeGPN], derived from the C. jejuni strain HSi and/or

HSI/44;

[~>3)-L-p-D-ido~Hep-(l->4)~p-D-GleNAc-(l >]_n, derived from

HS4/HS13/HS64, with non-stoichiometric substitution of O-methyl-phosphoramidate at position 2 of L-Dido-heptose;

[~-G)~0d~P-D~ido~Hep-{l ----»4)~p-D~GlcNAe~(lderived from HS4/13/64, with non-stoichiometxic MeOPN at C-2 and/or C~7 of 6d-ido-Hep;

WO 2016/022412

PCT/US2015/043070 [~-G)~L~P~D4dQ~Hep-(l ---->4)~p-D~GlcNAe~(lderived from HS4, with nonstoichiometric MeOPN at C-4 of LD-ido-Hep;

[—»3-6ά-β“ϋ”ίάθ”Η6ρ“(1“>4)”β-ϋ~θ1ο-(1“+]_η, derived from HS13, without MeOPN or with non-stoichiometric MeOPN at 02 and/or 07 of 6d-ido-Hep;

I (3,6,-O-Me)-D-glycero-a“L-glc-Hepp ' I

H2)-p-D-Rib/^:( 1 —5)-p~D-Gal/NAc-{ 1 —4-a-D-GicpA6-( 1 -*]_R 3 5

T T [MeOPN] [NGroNEtn], derived from HS2, whererin NGro = aminoglyeerol; Etn = ethanolamiue;

[—»3)-L-alpha~D-ido-Hep-(l->4)-alpha-GaI-( derived from HS3, with non-stoiehiomoetrie substitution Q-methyl-phosphoramidate at position 2 of 6deoxy-alpha-D-ido-heptose with or without a 3-hdroxypropanoyl ester at 03 of a-Gal;

[~*3)-L-P-D-idO”Hep-(l—»4)“P“D-Glc-(l”-*]_J!3 derived from HS50, with nonstoichiometric MeOPN at 04 of LD-ido-Hep;

and

WO 2016/022412

PCT/US2015/043070 [-~U“6d-P~D-ido-Hep~(l~-»4)~P~D-G!c“(l-->]_n, derived from HS50, with nonstoichiometric MeOPN at C-7 of 6d-ido-Hep, wherein the same polysaccharide is linked to form a polysaccharide polymer comprising 1 to 100 polysaccharides linked together (i.e,, “n” greater than or equal to 1);

b. administering a boosting dose of the composition as described in step (a), with or without adjuvant at a dose range of 0.1 pg to 10 mg per dose.

[0072] Another embodiment comprises a method of immunizing against Campylobacter jejuni strains HSI; HS1/HS44 and/or HS44 by the administration of a composition comprising one or more isolated C, jejuni capsule polysaccharides. The method comprises the steps:

a. administering an immunogenic composition comprising one or more C. jejuni capsule polysaccharide polymers. The C. jejuni capsule polysaccharide polymers comprise polysaccharide structures derived from capsules of C. jejuni strains selected from the group consisting of HSI, HS1/HS44, HS44, wherein a capsule polysaccharide polymer comprises 1 to 100 copies of a polysaccharide structure, derived from an individual C. jejuni strain, connected together to form a polymer, without lipooligosaecharide, or other structures associated with GBS administered at a dose range of 0.1 pg to 10 mg per dose with or without an adjuvant, The polysaccharide structures include one or more of the following structures selected from the structures:

[~-*4)-aD-GaI/?-(1—>2)-Gro-(l-~»P-~*]„, derived from the derived from the C.

jejuni strain HS44; or

WO 2016/022412

PCT/US2015/043070 [~-»4)~a-D~Galp~( 1 ™>2)-Gro-( 1 ~~>Ρ-··]_η 3 2

T T 1 1 [MeOPN]-+3)“Fruf Fru/-(3*-[MeOPN], derived from the C. jejuni strain HS1 and/or HS1/44;

wherein the same polysaccharide is linked to form a polysaccharide polymer comprising 1 to 100 polysaccharides linked together (i.e., “n” greater than or equal to 1);

b. administering a boosting dose of the composition as described in step (a), with or without adjuvant at a dose range of 0.1 pg to 10 mg per dose.

[0073] Another embodiment comprises a method of immunizing against Campylobacter jejuni strains HS4, HS13, HS4/HS13/H64 or HS50 by the administration of a composition comprising one or more isolated C. jejuni capsule polysaccharides derived from HS4, HS13, HS4/HS13/H64 or HS50. The method comprises the steps:

a. administering an immunogenic composition comprising one or more C. jejuni capsule polysaccharides derived from HS4, HS13, HS4/HS13/H64 or HS50, wherein a capsule polysaccharide polymer compriseing 1 to 100 copies of a polysaccharide structure, connected together to form a polymer, without lipooligosaecharide, or other structures associated with GBS, administered at a dose range of 0.1 pg to 10 mg per dose

WO 2016/022412

PCT/US2015/043070 with or without an adjuvant and wherein the polysaccharide structures include one or more of the following structures selected from the structures:

[->3)-L-p-D-ido-Hep-(l->4)-P-D-GlcNAc~(l--*]_n, derived from HS4/HS13/HS64, with non-stoichiometrie substitution of O-methyl~phosphoramidate at position 2 of L-D-ido-heptose;

[-~>3)-6d-p-D-ido-Hep-(l--»4)-P-D~GlcNAe~(l—>]_n, derived from HS4/13/64, with non-stoichiometric MeOPN at C-2 and/or C-7 of dd-ido-Hep;

[“*3)~L~3-D-idO“Hep-(l—+4)-P-D-GleNAc-(l“->]_r!, derived from HS4, with nonstoichiometric MeOPN at C-4 of LD-ido-Hep;

[~~»3-6d-P-D-ido-Hep-(l--»4)-P~D-Glc-(l—»]_n, derived from HS13, without MeOPN or with non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-ido-Hep;

[™»3)-L-P-D-ido-Hep-(1 “^4)-P-D~Gle~(l—·>]ι„ derived from HS50, with nonstoichiometric MeOPN at C-4 of LD-ido-Hep; and [--»3-6d-P-D-ido-Hep-(l-~*4)-p-D-GIe-(l—-»]_ES, derived from HS50, with nonstoichiometric MeOPN at C-7 of 6d-ido-Hep,

WO 2016/022412

PCT/US2015/043070 wherein the same polysaccharide is linked to form a polysaccharide polymer comprising 1 to 100 polysaccharides linked together (i.e., “n” greater than or equal to 1);

b. administering a boosting dose of the composition as described in step (a), with or without adjuvant at a dose range of 0.1 gg to 10 mg per dose.

[0074] The polysaccharide polymers can be conjugated or unconjugated to a carrier molecule and the composition. In the above method, immunogenic composition can be administered orally, nasally, subcutaneously, intradermally, transdermally, transcutaneously, intramuscularly or rectally. Also, the carrier molecule can be a protein, for example CRM <97, or a non-protein molecule. Adjuvants can be any of a number of adjuvants. Examples of adjuvants include: LTR 192G, Aluminum hydroxide, RC529E, QS21, E294, olgodeoxynucleotides (ODN), CpG-containing oligodeoxynucleotides, and aluminum phosphage, [0075] Obviously, many modifications and variations of the present invention are possible, in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

2015301368 07 Mar 2018

Claims (21)

1. CLAIMS:

   1. An immunogenic composition against Campylobacter jejuni, comprising one or more polysaccharide antigens, wherein each of said polysaccharide antigens comprises an isolated Campylobacter jejuni capsule polysaccharide derived from a Campylobacter jejuni strain linked to form a repeating polysaccharide polymer comprising 2 or more of said capsule polysaccharides, wherein said Campylobacter jejuni strains are selected from the group consisting of: HS4, HS5, HS4/13/64, and HS50, wherein said immunogenic composition does not contain Campylobacter jejuni lipooligosaccharide structures associated with Guillain Barre Syndrome, wherein the structure of HS4 Is —>3)-L-p-D-ido Hep-( 1 —»4)-P-D-GlcNAc-(lwith non-stoichiometric MeOPN at C-4 of LD-ido-Hep, wherein the structure of HS4/13/64 is [—>3)-6d-3-D-ido-Hep-(l—>4)-P-D-GlcNAc-(l—>]_n, with non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-ido-Hep, and wherein the number of repeats of a capsule polysaccharide “n” is 1 to 100.
2. 2. The immunogenic composition of claim 1, wherein said isolated Campylobacter jejuni capsule polysaccharide comprises a polysaccharide structure selected from the group consisting of:

   [Mc0PN]—

   I i

   -* 7)a-DD-Hep( 1 -»3)Glucitol(6 -+ P —* α-Dideoxy-Hep a-Dideoxy-Hep [MeOPN]— [MeOPN]— (14389708_l):GGG

   2015301368 07 Mar 2018 [MeOPN]”· α-Did^oxy-Hep

   -»7)a-DD-Hep(l -»2)Glucitol(6 ->P — 2 I 1 a-Dideoxy-Hep

   T [MeOPN]”7)a-DD-Hep( 1 -* 2)Glucitol(6 -»P -*

   T a-Dideoxy-Hep

   T [MeOPN]”·

   -* 7)a-DD-Hep(l — 3)GlucitoI(6 -> P —

   2 2

   T t

   1 1 a-Dideoxy-Hep a-Dideoxy-Hep 7 7 [MeOPN]”- [MeOPN]”- _derived f_{rom H}S5;

   [—>3)-L-P-D-ido-Hep-(l->4)-P-D-Glc-(l—>]_n, derived from HS50, with nonstoichiometric MeOPN at C-4 of LD-ido-Hep; and [—>3-6d-p-D-ido-Hep-(l—>4)-p-D-Glc-(l—>]_n, derived from HS50, with nonstoichiometric MeOPN at C-7 of 6d-ido-Hep, wherein the number of repeats of a capsule polysaccharide “n” is 1 to 100.
3. 3. The immunogenic composition of claim 1 or claim 2, wherein said capsule polysaccharide is conjugated to a protein carrier.
4. 4. The immunogenic composition of claim 3, wherein said protein carrier is CRM197.
5. 5. The immunogenic composition of claim 1 or claim 2, wherein said immunogenic composition also comprises an adjuvant.

   (14389708_l):GGG

   2015301368 07 Mar 2018
6. 6. The immunogenic composition of claim 5, wherein said adjuvant is selected from the group consisting of LTR192G, aluminum hydroxide, RC529, QS21, E294, oligodeoxynucleotides (ODN), CpG-containing oligodeoxynucleotides, and aluminum phosphate.
7. 7. A method of inducing an an\\-Campylobacter jejuni immune response in a mammal against a Campylobacter jejuni strain selected from the group consisting of HS4, HS5, HS4/13/64, and HS50, comprising:

   a. administering the immunogenic composition of claim 1 or claim 2 to said mammal at a dose range of 0.1 pg to 10 mg per dose; and

   b. administering a boosting dose of said immunogenic composition of claim 1 or claim 2 to said mammal at a dose range of 0.1 pg to 10 mg per dose.
8. 8. The method of claim 7, wherein said capsule polysaccharide is conjugated to a protein carrier.
9. 9. The method of claim 8, wherein said protein carrier is CRM197.
10. 10. The method of claim 7, wherein said immunogenic composition also comprises an adjuvant.
11. 11. The method of claim 10, wherein said adjuvant is selected from the group consisting of LTR192G, aluminum hydroxide, RC529, QS21, E294, oligodeoxynucleotides (ODN), CpG-containing oligodeoxynucleotides, and aluminum phosphate.
12. 12. The method of claim 7, wherein said immunogenic composition is administered by a route selected from the group consisting of: orally, nasally, subcutaneously, intradermally, transdermally, transcutaneously, intramuscularly and rectally.
13. 13. A method of inducing an ΆΏή-Campylobacter jejuni immune response in a mammal against a Campylobacter jejuni strain selected from the group consisting of HS4, HS4/13/64, HS5, and HS50, comprising administering 3 doses of the immunogenic composition of claim 1 or claim 2 to said mammal, at a dose range of 0.1 pg to 10 mg per dose, with or without an adjuvant.
14. 14. The method of claim 13 wherein said capsule polysaccharide is conjugated to a protein carrier.
15. 15. The method of claim 14, wherein said protein carrier is CRM197.

    (14389708_l):GGG

    2015301368 07 Mar 2018
16. 16. The method of claim 13, wherein said adjuvant is selected from the group consisting of LTR192G, aluminum hydroxide, RC529, QS21, E294, oligodeoxynucleotides (ODN), CpG-containing oligodeoxynucleotides, and aluminum phosphate.
17. 17. The method of claim 13, wherein said immunogenic composition is administered by a route selected from the group consisting of: orally, nasally, subcutaneously, intradermally, transdermally, transcutaneously, intramuscularly and rectally.
18. 18. Use of an immunogenic composition of claim 1 or claim 2 in the manufacture of a medicament for inducing an anti-Campylobacter jejuni immune response in a mammal against a Campylobacter jejuni strain selected from the group consisting of HS4, HS4/13/64, HS5, and HS50, wherein in said inducing an immune response two doses or three doses of said composition are administered to said mammal, at a dose range of 0.1 gg to 10 mg per dose, with or without an adjuvant.

    The United States of America as represented by the Secretary of the Navy

    Patent Attorneys for the Applicant/Nominated Person

    SPRUSON & FERGUSON (14389708_l):GGG

    HS10102 03 04 05 05 07 SS SS 10 11

    WO 2016/022412

    PCT/US2015/043070

    HS44 0102 03 04 05 06 07 08 09 10 11 12 13 1415 26 17 18 19 20

    FIG. I

    SUBSTITUTE SHEET (RULE 26)

    1/21

    WO 2016/022412

    PCT/US2015/043070

    FIG. 2

    SUBSTITUTE SHEET (RULE 26)

    2/21

    WO 2016/022412

    PCT/US2015/043070

    O SA 5.2 Ο

    FIG. 3

    SUBSTITUTE SHEET (RULE 26)

    3/21

    WO 2016/022412

    PCT/US2015/043070

    FIG. 4

    4/21

    WO 2016/022412

    PCT/US2015/043070

    FIG. 5

    SUBSTITUTE SHEET (RULE 26)

    5/21

    WO 2016/022412

    PCT/US2015/043070

    Relative Abundance

    100;;, 90 80 B © Λ ?o ί ο φ 53 60 TS ώ 9k 50 40 30 20 10 m

    30 35 40 45 50

    Time (min)

    FIG. 6

    6/21

    WO 2016/022412

    PCT/US2015/043070

    IN

    Deoxv Resonances ^K«N

    V.

    FIG. 7

    7/21

    WO 2016/022412

    PCT/US2015/043070

    5.0 4.5

    FIG. 8

    4.0

    SUBSTITUTE SHEET (RULE 26)

    8/21

    WO 2016/022412

    PCT/US2015/043070 «>«> d d

    FIG. 9

    SUBSTITUTE SHEET (RULE 26)

    9/21

    WO 2016/022412

    PCT/US2015/043070

    FIG. 10

    10/21

    WO 2016/022412

    PCT/US2015/043070 [MeOPN] s-DideoxV’Hep a-Dideoxy-Hep i -* 7)a-DD-Hep(l 3)GIudtol(6 P

    A ¢) X 7>DD~Hep(l -* 2)Ghei e

    α-Dideoxy-Hep a-Dideoxy-Hep t

    a-Dideoxy«Hep [MeOPN]' [MeOPN]'' (MeOPN]''

    7)a-DI>Hep(l -·> 2)Glucstol(6 ~~> P

    7)et-DD-Hep(i 3)GIuciiol(6 ?

    a-Dideoxv-Hep 7 x [MeOPN]-a-Dideoxy-Hep a»Dideoxy»Hep [MeOPN]'· [MeOPN]'FIG. 11

    SUBSTITUTE SHEET (RULE 26)

    11/21

    WO 2016/022412

    PCT/US2015/043070

    Relative Abundance

    100 ⁹⁵1 SO 85 80.

    75/

    70 /

    857

    807

    55/ ⁵⁰ -i;

    45/

    407

    357

    30/

    257 20 /

    15/

    10/

    0 7— 32 £

    »£ '£

    I £

    a x

    ΐ

    36 3S

    40 42 44 46

    Time (min)

    50 52 S4

    FIG. 12

    12/21

    WO 2016/022412

    PCT/US2015/043070

    FIG. 13

    SUBSTITUTE SHEET (RULE 26)

    13/21

    WO 2016/022412

    PCT/US2015/043070 aw

    FIG. 14

    14/21

    WO 2016/022412

    PCT/US2015/043070

    5.8

    4,0 ppm

    FIG. 15

    SUBSTITUTE SHEET (RULE 26)

    15/21

    WO 2016/022412

    PCT/US2015/043070

    FIG. 16

    16/21

    WO 2016/022412

    PCT/US2015/043070 aye)

    5.3 5,2 5,5 5,8 4.9 4.8 4.? 4.3 45 44 45 4.Ϊ 4.1 -1.3 3,3 3.8 3.? 3.3 fjjsn 1_H

    FIG. 17

    17/21

    WO 2016/022412

    PCT/US2015/043070 p«Q,OS art M2 PS

    10 pg 5Spg

    3«wk 3rd hmwriaiba

    HS1 HS1 kp$M

    FIG. 18

    SUBSTITUTE SHEET (RULE 26)

    18/21

    WO 2016/022412

    PCT/US2015/043070

    FIG, 19

    SUBSTITUTE SHEET (RULE 26)
19. 19/21

    WO 2016/022412

    PCT/US2015/043070 afSrSr

    Recprosa! Endpoint Tier

    2wk post 3rd te muriaaiao

    SUBSTITUTE SHEET (RULE 26)
20. 20/21

    WO 2016/022412

    PCT/US2015/043070 *

    Swlc post 3rd immunte&n

    FIG. 21

    SUBSTITUTE SHEET (RULE 26)
21. 21/21